Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

  • Awaiting development
  • GID-TA11747
  • Expected publication date: 
To appraise the clinical and cost effectiveness of Durvalumab within its marketing authorisation for treating non-small-cell lung cancer